Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative
The landscape of ALL has evolved significantly from both the biologic and treatment standpoint. This session will focus on the increasing incorporation of minimal residual disease (MRD) into treatment decisions for ALL. In addition, we will discuss strategies being explored in patients with newly diagnosed and relapsed/ refractory ALL: the addition of novel agents into treatment, the use of pediatric regimens in adult ALL, and treatment with second and third generation tyrosine kinase inhibitors (TKIs) in Philadelphia-chromosome (Ph)+ ALL.
Dr. Anjali Advani will discuss the prognostic impact of MRD and its use in treatment decisions. She will also discuss the novel agents: antibody-based treatments (blinatumomab and inotuzumab), bcl-2 inhibitors, and TKIs (for Ph-like ALL) and their incorporation into the treatment of ALL.
Dr. Lori Muffly will summarize the results of recent trials evaluating pediatric-inspired regimens in adults with ALL and the steps moving forward in this arena.
Dr. Adele Fielding will review the promising results with second and third generation TKIs in combination with chemotherapy for Ph+ ALL and the controversies surrounding the question of allogeneic hematopoietic stem cell transplant for these patients.
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members